Parabilis Medicines, Inc. (PBLS) discovers, develops, or markets pharmaceutical products. PBLS stock sits in Health Care (Pharmaceutical Preparations), listed on Nasdaq.

Parabilis Medicines, Inc. financial statements — income statement, balance sheet, and cash flow — are on this PBLS stock page, parsed from SEC 10-K and 10-Q filings. Use Annual or Quarterly, then the statement tabs. Research only.

This page is a research snapshot of Parabilis Medicines, Inc. (PBLS) from the latest SEC filings in the Misprise database as of TTM. It is not a news feed or a delisting notice. Open the financial statements, chart, and peer compare below, then read the filings. Research only — not financial advice.

The live chart on this PBLS stock page is the same TradingView chart as the screener. Statement tables use SEC filings. Any price or multiple on the TTM column is a market snapshot from the last seed, not a real-time quote. Research only.

Parabilis Medicines, Inc. is classified in Pharmaceutical Preparations, inside the Health Care sector, and trades on Nasdaq. This page is a research snapshot, not a full company profile.

Start with this ticker’s block (TTM, then its fiscal years or quarters). Each Compare name is a separate block of its own periods — not mixed by year. A blank is a period we do not have, not a zero. Research only — not a buy or sell.

Income, balance sheet, and cash-flow lines are parsed from SEC company filings (10-K / 10-Q and 20-F). TTM is the last four reported quarters added together, not a separate filing. P/E, forward P/E, price, and market cap are a market quote at last seed — trailing P/E from the quote when available, otherwise last price divided by TTM EPS. They are not 10-K line items and appear on the TTM column only. Research only — not financial advice.

On this PBLS stock page, open Financial statements and use the Income, Balance sheet, and Cash flow tabs. Growth and valuation sit under More. Filing figures are from SEC reports; valuation multiples are the market snapshot described above.

PBLS stock currently scores 29/100 (Watch / incomplete (<60)). Parabilis Medicines, Inc. scores weaker or incomplete on durable growth/quality inputs — leverage, coverage, and recent results deserve extra scrutiny. The score is a screen of quality, growth, and balance-sheet inputs — not a price target. Compare it in the Misprise screener; it is not a separate score page.

Lead and Tie follow the number printed on each factor row, not a blended category score. Growth, quality, score, current ratio, and coverage: the higher figure leads. Value multiples (P/E, PEG, P/B, P/S) and debt ratios: the lower figure leads. Tie appears only when those printed numbers match. The header winner is whoever takes more of those five rows. CAGR uses the 5-year horizon and drops to 3-year only when both names report it. Research only — not a buy or sell.

Anomaly Score is how unusual a filing pattern is versus this company’s own history and its industry — not the same as Misprise Score. A high anomaly with a weak Misprise Score is often a noisy name. Open the anomaly detector to see the flag. Research only — not financial advice.

A green circle next to the title means this ticker appears in the Misprise grants calendar with a recent federal award (USASpending / SAM). Tap the dot for date, agency, and amount when available. It is a research flag only — not a buy or sell signal.

No recommendation either way. This PBLS stock page organizes statements, ratios, and peers so you can do your own work. It is educational only — not advice to buy or sell Parabilis Medicines, Inc..